-
21.发明申请METHODS FOR THE INACTIVATION OF MICROORGANISMS IN BIOLOGICAL FLUIDS, FLOW THROUGH REACTORS AND METHODS OF CONTROLLING THE LIGHT SUM DOSE TO EFFECTIVELY INACTIVATE MICROORGANISMS IN BATCH REACTORS 有权生物流体中微生物灭活的方法，通过反应器流动的方法和控制轻剂量以有效地使分批反应器中的微生物失活的方法公开(公告)号：US20110206554A1
公开(公告)日：2011-08-25
申请号：US13100570
申请日：2011-05-04
申请人： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel R. Boggs
发明人： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel R. Boggs
CPC分类号： A61L2/10 , A23L3/26 , A23L3/28 , A61L2/0011 , A61L2/28 , G01N21/33 , H05B3/0052
摘要： The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
摘要翻译： 本发明涉及一种用于确定来自一种或多种光源的有效剂量的单色或多色光以灭活存在于生物流体中，优选非透明流体中的微生物的方法。 此外，提供了在流通反应器中的生物流体中的微生物灭活的方法。 此外，本发明有利地提供具有一个或多个恒温光源的流通反应器。 本发明还提供一种控制从一个或多个光源发射的单色或多色光的光总量的方法，以有效地灭活间歇反应器中存在于生物流体中的微生物。
-
22.发明授权IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease 有权用于治疗多发性硬化，阿尔茨海默氏病和帕金森病的趋化因子的IVIG调节公开(公告)号：US07968293B2
公开(公告)日：2011-06-28
申请号：US12189367
申请日：2008-08-11
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
摘要翻译： 本发明提供用于提供治疗与脑炎性疾病相关疾病（包括MS）的预后的方法，例如使用显示为过表达的分子标记物复发性缓解多发性硬化（RRMS），阿尔茨海默氏病和帕金森病 或在静脉注射免疫球蛋白（IVIG）治疗的患者中未表达。 还提供了鉴定可用于治疗或预防MS的化合物的方法，例如复发缓解多发性硬化症（RRMS），阿尔茨海默病和帕金森病。
-
23.发明授权Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV 有权表现出von Willebrand因子（vWF）蛋白酶活性的组合物，其包含具有氨基酸序列AAGGILHLELLV的多肽链公开(公告)号：US07910094B2
公开(公告)日：2011-03-22
申请号：US12370129
申请日：2009-02-12
申请人： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
发明人： Bernhard Laemmle , Helena Elisabeth Schaller-Gerritsen , Miha Furlan , Peter Turecek , Hans-Peter Schwarz , Friedrich Scheiflinger , Gerhard Antoine , Randolf Kerschbaumer , Luigina Tagliavacca , Klaus Zimmermann
CPC分类号： A61K38/4886 , A61K38/00 , C07K14/755 , C07K16/36 , C12N9/6416 , C12N9/6489 , C12Y304/24087
摘要： The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
摘要翻译： 本发明涉及分子量为180kD，170kD，160kD，120kD或110kD的VWF切割实体以及AAGGILHLELLV的N-末端氨基酸序列，vWF切割复合物及其生产方法。
-
24.发明申请Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof 有权透明质酸酶和免疫球蛋白的稳定共配方及其使用方法公开(公告)号：US20110066111A1
公开(公告)日：2011-03-17
申请号：US12807991
申请日：2010-09-16
申请人： Wolfgang Teschner , Sonja Svatos , Leopold Bruckschwaiger , Alfred Weber , Hans-Peter Schwarz , Laura Lei
发明人： Wolfgang Teschner , Sonja Svatos , Leopold Bruckschwaiger , Alfred Weber , Hans-Peter Schwarz , Laura Lei
CPC分类号： A61K39/00 , A61K9/0021 , A61K39/39591 , A61K47/42 , A61K2039/505 , C07K16/00 , C07K16/06 , C07K2317/21 , C12N9/2474 , C12Y302/01035 , Y02A50/464
摘要： Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.
摘要翻译： 本文提供了免疫球蛋白和透明质酸酶的稳定共配方，其在室温下以液体形式储存至少6个月，并在标准冰箱温度下保存1-2年。 这种共同制剂可用于通过皮下给药治疗IG治疗性疾病或病症的方法。
-
25.发明申请METHODS OF DETERMINING POLYDISPERSITY AND/OR MOLECULAR WEIGHT DISTRIBUTION OF A POLYETHYLENE GLYCOL SAMPLE 审中-公开确定聚乙二醇样品多聚性和/或分子量分布的方法公开(公告)号：US20100126866A1
公开(公告)日：2010-05-27
申请号：US12621051
申请日：2009-11-18
申请人： Jasmin Kemptner , Martina Marchetti-Deschmann , Juergen Siekmann , Peter Turecek , Hans-Peter Schwarz , Guenter Allmaier
发明人： Jasmin Kemptner , Martina Marchetti-Deschmann , Juergen Siekmann , Peter Turecek , Hans-Peter Schwarz , Guenter Allmaier
IPC分类号： B01D59/42
CPC分类号： G01N27/624
摘要： Disclosed herein are methods of determining polydispersity (PDI) and molecular mass distribution (MMD) of reactive PEG samples using mass spectrometry. More specifically, a mass spectrometry method called GEMMA is used to determine PDI and MMD of PEG samples which provides more accurate measurements for high molecular weight PEG samples than prior known MALDI-TOF analysis.
摘要翻译： 本文公开了使用质谱测定反应性PEG样品的多分散性（PDI）和分子量分布（MMD）的方法。 更具体地，使用称为GEMMA的质谱法来测定PEG样品的PDI和MMD，其提供了比现有已知的MALDI-TOF分析更高精度的高分子量PEG样品的测量。
-
26.发明申请公开(公告)号：US20100115637A1
公开(公告)日：2010-05-06
申请号：US12606884
申请日：2009-10-27
CPC分类号： A61K49/0008 , A01K67/027 , A01K67/0275 , A01K67/0276 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , A01K2267/0325 , A01K2267/0381 , C12N15/8509
摘要： The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
摘要翻译： 本发明涉及用于测试治疗凝血障碍的各种药剂的动物模型的开发。 更具体地，本发明涉及在各种小鼠品系中使用超大分子量多聚体维生素B因子（VWF）以诱导血小板减少性紫癜（TTP）样症状，用于开发TTP小鼠模型。 本发明还提供了产生用于鉴定有效治疗TTP的生物活性化合物的动物疾病模型和筛选方法。
-
27.发明申请IVIG MODULATION OF CHEMOKINES FOR TREATMENT OF MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, AND PARKINSON'S DISEASE 有权用于治疗多发性硬化症，阿尔茨海默病和帕金森病的化疗药物的IVIG调节公开(公告)号：US20090148463A1
公开(公告)日：2009-06-11
申请号：US12189367
申请日：2008-08-11
IPC分类号： A61K39/395 , G01N33/53 , A61P25/00 , A61P37/06 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
摘要翻译： 本发明提供用于提供治疗与脑炎性疾病相关疾病（包括MS）的预后的方法，例如使用显示为过表达的分子标记物复发性缓解多发性硬化（RRMS），阿尔茨海默氏病和帕金森病 或在静脉注射免疫球蛋白（IVIG）治疗的患者中未表达。 还提供了鉴定可用于治疗或预防MS的化合物的方法，例如复发缓解多发性硬化症（RRMS），阿尔茨海默病和帕金森病。
-
28.发明授权公开(公告)号：US07033590B1
公开(公告)日：2006-04-25
申请号：US09661992
申请日：2000-09-14
申请人： Friedrich Scheiflinger , Randolf Kerschbaumer , Falko-Guenter Falkner , Friedrich Dorner , Hans-Peter Schwarz
发明人： Friedrich Scheiflinger , Randolf Kerschbaumer , Falko-Guenter Falkner , Friedrich Dorner , Hans-Peter Schwarz
IPC分类号： A61K39/395 , A61K38/04 , C12N5/20 , C07K16/00 , C07K16/34
CPC分类号： C07K16/40 , A61K2039/505
摘要： An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
摘要翻译： 针对因子IX /活化因子IX（FIXa）的抗体或抗体衍生物，其增加FIXa的促凝血活性。
-
公开(公告)号：US20060045796A1
公开(公告)日：2006-03-02
申请号：US10924579
申请日：2004-08-24
申请人： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
发明人： Heinz Anderle , Peter Matthiessen , Hans-Peter Schwarz , Peter Turecek , Thomas Kreil , Daniel Boggs
CPC分类号： A61L2/10 , A23L3/26 , A23L3/28 , A61L2/0011 , A61L2/28 , G01N21/33 , H05B3/0052
摘要： The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
-
公开(公告)号：US20060003921A1
公开(公告)日：2006-01-05
申请号：US11218406
申请日：2005-09-02
IPC分类号： A61K38/37
CPC分类号： A61K38/37
摘要： Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
摘要翻译： 描述了一种用于治疗凝血障碍的药物制剂，其包含有效量的vWF前肽以及制备这种制剂的方法。
-
-
-
-
-
-
-
-
-
搜索结果
113 条记录 (耗时 0.049 秒)
